Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Integra Lifesciences HoldingsIART +2.01%70 PB Ratio is 1.40 as of Jul. 16, 2026, which is 55% below its 10-year median of 3.11. GuruFocus rates IART with a GF Score™ of 70/100 and a GF Value™ of $23.81 (Modestly Undervalued). The stock has 11 warning signs investors should review. Among 787 Medical Devices & Instruments companies, Integra Lifesciences Holdings ranks better than 68.49% on this metric.
Integra Lifesciences Holdings Corp stock PB Ratio (=1.37) is close to 1-year high of 1.4.
The historical rank and industry rank for Integra Lifesciences Holdings's PB Ratio or its related term are showing as below:
IART'
s PB Ratio Range Over the Past 10 Years
Min: 0.59 Med: 3.11 Max: 5.31
Current: 1.4
During the past 13 years, Integra Lifesciences Holdings's highest PB Ratio was 5.31. The lowest was 0.59. And the median was 3.11.
IART's PB Ratio is ranked better than 68.49% of 787
companies
in the Medical Devices & Instruments industry
Industry Median: 2.05
vs IART: 1.40
During the past 12 months, Integra Lifesciences Holdings's average Book Value Per Share Growth Rate was -31.70% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -14.70% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was -4.20% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was 5.60% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Integra Lifesciences Holdings was 74.80% per year. The lowest was -19.20% per year. And the median was 7.90% per year.
Back to Basics: PB Ratio
Integra Lifesciences Holdings (NAS:IART) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Integra Lifesciences Holdings PB Ratio Related Terms
Integra Lifesciences Holdings PB Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Integra Lifesciences Holdings's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Integra Lifesciences Holdings PB Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Integra Lifesciences Holdings's PB Ratio distribution charts can be found below:
* The bar in red indicates where Integra Lifesciences Holdings's PB Ratio falls into.
Integra Lifesciences Holdings PB Ratio Calculation
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Integra Lifesciences Holdings (IART) has a PB Ratio of 1.40 as of Jul. 16, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Integra Lifesciences Holdings and its competitors. This is 55% below median its historical median of 3.11. Over the past decade, Integra Lifesciences Holdings' PB Ratio has ranged from 0.59 to 5.31. According to the industry distribution chart, Integra Lifesciences Holdings ranks #248 out of 787 companies in the Medical Devices & Instruments industry, placing it in the top 31.5%.
Is Integra Lifesciences Holdings' PB Ratio too high?
Integra Lifesciences Holdings' current PB Ratio of 1.40 is 55% below median its 10-year median of 3.11. Over the past 10 years, this metric has ranged from a low of 0.59 to a high of 5.31. The Medical Devices & Instruments industry median PB Ratio is 2.05. Integra Lifesciences Holdings' value of 1.40 is 31.7% below this industry median. Based on the distribution chart, Integra Lifesciences Holdings ranks #248 out of 787 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Integra Lifesciences Holdings has a GF Score™ of 70/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Integra Lifesciences Holdings' PB Ratio compare to ATEC and AHCO?
According to the Medical Devices & Instruments industry distribution chart, Integra Lifesciences Holdings ranks #248 out of 787 companies for PB Ratio. This puts Integra Lifesciences Holdings in the upper half of its industry. The industry median PB Ratio is 2.05. Integra Lifesciences Holdings' value of 1.40 is 31.7% below this benchmark. Historically, Integra Lifesciences Holdings' own PB Ratio has ranged from 0.59 to 5.31 over the past decade. While the company's 10-year median is 3.11 vs. the industry median of 2.05, Integra Lifesciences Holdings has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Medical Devices & Instruments company?
The median PB Ratio among Medical Devices & Instruments companies is 2.05, based on 787 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Integra Lifesciences Holdings's current PB Ratio of 1.40 is 31.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Integra Lifesciences Holdings and its competitors. For the Medical Devices & Instruments industry, the median PB Ratio is 2.05 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Integra Lifesciences Holdings's current PB Ratio is 1.40, which is 55% below median its own 10-year median of 3.11. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Integra Lifesciences Holdings stock overvalued right now?
Based on GuruFocus' analysis, Integra Lifesciences Holdings (IART) is currently considered Modestly Undervalued. The stock's GF Value™ is $23.81, compared to a current price of $18.78 — trading 21.1% below its estimated fair value. The current PB Ratio is 1.40, which is 55% below median its 10-year median of 3.11 and 31.7% below the Medical Devices & Instruments industry median of 2.05. Integra Lifesciences Holdings' overall GF Score™ is 70/100 with 11 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Integra Lifesciences Holdings (IART), the current PB Ratio is 1.40 as of Jul. 16, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Integra Lifesciences Holdings (IART) Overvalued in 2026?
Based on GuruFocus' analysis, Integra Lifesciences Holdings stock appears to be undervalued.
The current stock price of $18.78 is trading 21.1% below its estimated GF Value™ of $23.81.
GuruFocus considers Integra Lifesciences Holdings to be Modestly Undervalued.
Key valuation signals for IART:
PB Ratio: 1.40 (55% below median its 10-year median of 3.11)
GF Value™: $23.81 vs. price of $18.78 (21.1% below fair value)
Industry Position: 31.7% below the Medical Devices & Instruments median (#248 of 787)
No single metric tells the full story. See the IART stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Integra Lifesciences Holdings Business Description
Integra Lifesciences Holdings Corp is a New Jersey-based medical equipment company focused on developing products for regenerative therapy, extremity orthopedics, and neurosurgical applications. The firm is organized into two primary segments: Codman specialty surgical and Tissue technologies. Codman Specialty Surgical generates maximum revenue from its segmental operations. Integra serves Europe, Asia Pacific, and the rest of the world whilst it derives key revenue from domestic sales. The company operates in United States, Europe, Asia Pacific, and Rest of the World.
70GF Score
Get the complete analysis for IART
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
IART has been successfully added to your 
